117 related articles for article (PubMed ID: 23616084)
41. Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Patnaik A; Rowinsky EK; Tammara BK; Hidalgo M; Drengler RL; Garner AM; Siu LL; Hammond LA; Felton SA; Mallikaarjun S; Von Hoff DD; Eckhardt SG
J Clin Oncol; 2000 Dec; 18(23):3974-85. PubMed ID: 11099327
[TBL] [Abstract][Full Text] [Related]
42. Phase I study of veliparib in combination with gemcitabine.
Stoller R; Schmitz JC; Ding F; Puhalla S; Belani CP; Appleman L; Lin Y; Jiang Y; Almokadem S; Petro D; Holleran J; Kiesel BF; Ken Czambel R; Carneiro BA; Kontopodis E; Hershberger PA; Rachid M; Chen A; Chu E; Beumer JH
Cancer Chemother Pharmacol; 2017 Sep; 80(3):631-643. PubMed ID: 28770300
[TBL] [Abstract][Full Text] [Related]
43. Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer.
Nemunaitis JJ; Orr D; Eager R; Cunningham CC; Williams A; Mennel R; Grove W; Olson S
Cancer J; 2003; 9(1):58-66. PubMed ID: 12602769
[TBL] [Abstract][Full Text] [Related]
44. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Abdul Razak AR; Miller WH; Uy GL; Blotner S; Young AM; Higgins B; Chen LC; Gore L
Invest New Drugs; 2020 Aug; 38(4):1156-1165. PubMed ID: 31734832
[TBL] [Abstract][Full Text] [Related]
45. The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Dumez H; Louwerens M; Pawinsky A; Planting AS; de Jonge MJ; Van Oosterom AT; Highley M; Guetens G; Mantel M; de Boeck G; de Bruijn E; Verweij J
Anticancer Drugs; 2002 Jul; 13(6):583-93. PubMed ID: 12172503
[TBL] [Abstract][Full Text] [Related]
46. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.
O'Reilly EM; Roach J; Miller P; Yu KH; Tjan C; Rosano M; Krause S; Avery W; Wolf J; Flaherty K; Nix D; Ryan DP
Oncologist; 2017 Dec; 22(12):1429-e139. PubMed ID: 29158367
[TBL] [Abstract][Full Text] [Related]
47. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors.
Schelman W; Morgan-Meadows S; Bailey H; Holen K; Thomas JP; Eickhoff J; Brandon H; Oliver K; Alberti D; Wilding G
Cancer Chemother Pharmacol; 2008 Sep; 62(4):727-33. PubMed ID: 18172649
[TBL] [Abstract][Full Text] [Related]
48. A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma.
Borad MJ; Babiker HM; Anthony S; Mita M; Buchbinder A; Keilani T; Grem J
Cancer Invest; 2015 May; 33(5):172-9. PubMed ID: 25844818
[TBL] [Abstract][Full Text] [Related]
49. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Bellmunt J; Suarez C; Gallardo E; Rodon J; Pons F; Bonfill T; Beltran M; Moya I; Galtes S; Albanell J; Carles J
Oncologist; 2014 Sep; 19(9):917-8. PubMed ID: 25142843
[TBL] [Abstract][Full Text] [Related]
50. Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
Schmid P; Schweigert M; Beinert T; Flath B; Sezer O; Possinger K
Invest New Drugs; 2005 Mar; 23(2):139-46. PubMed ID: 15744590
[TBL] [Abstract][Full Text] [Related]
51. Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Santini D; Vincenzi B; Schiavon G; La Cesa A; Gasparro S; Vincenzi A; Tonini G
BMC Cancer; 2006 Feb; 6():42. PubMed ID: 16504126
[TBL] [Abstract][Full Text] [Related]
52. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study.
Winer ES; Safran H; Karaszewska B; Richards DA; Hartner L; Forget F; Ramlau R; Kumar K; Mayer B; Johnson BM; Messam CA; Mostafa Kamel Y
Cancer Med; 2015 Jan; 4(1):16-26. PubMed ID: 25165041
[TBL] [Abstract][Full Text] [Related]
53. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Galsky MD; Posner M; Holcombe RF; Lee KM; Misiukiewicz K; Tsao CK; Godbold J; Soto R; Gimpel-Tetra K; Lowe N; Oh WK
Cancer Chemother Pharmacol; 2014 Sep; 74(3):465-71. PubMed ID: 25023489
[TBL] [Abstract][Full Text] [Related]
54. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
[TBL] [Abstract][Full Text] [Related]
55. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
56. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Lim N; Lara PN; Lau DH; Edelman MJ; Tanaka M; al-Jazayrly G; Houston J; Lauder I; Gandara DR
Cancer Invest; 2003; 21(1):7-13. PubMed ID: 12643004
[TBL] [Abstract][Full Text] [Related]
57. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
58. Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
Baka S; Manegold C; Buchholz E; Schott-von-Römer K; Lorigan P; Nagel S; Blackhall F; Aschroft L; Thatcher N
Lung Cancer; 2006 Aug; 53(2):165-70. PubMed ID: 16787686
[TBL] [Abstract][Full Text] [Related]
59. A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
Saif MW; Sellers S; Li M; Wang W; Cusimano L; Wang H; Zhang R
Cancer Chemother Pharmacol; 2007 Nov; 60(6):871-82. PubMed ID: 17345085
[TBL] [Abstract][Full Text] [Related]
60. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
Mom CH; Verweij J; Oldenhuis CN; Gietema JA; Fox NL; Miceli R; Eskens FA; Loos WJ; de Vries EG; Sleijfer S
Clin Cancer Res; 2009 Sep; 15(17):5584-90. PubMed ID: 19690193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
